Immunogenetics of prostate cancer: a still unexplored field of study. (February 2018)

• Record Type: Journal Article
• Authors: Dreussi, Eva; Ecca, Fabrizio; Scarabel, Lucia; Gagno, Sara; Toffoli, Giuseppe
• Is Part Of: Pharmacogenomics. Volume 19:Number 3(2018)
• Page Start: 263
• Page End: 283
• Publication Date: 2018-02
• Subjects: immune system -- polymorphisms -- prostate cancer; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs-2017-0163
• Languages: English
• ISSNs: 1462-2416

Abstract

The immune system is a double-edged sword with regard to the prostate cancer (PCa) battle. Immunogenetics, the study of the potential role of immune-related polymorphisms, is taking its first steps in the treatment of this malignancy. This review summarizes the most recent papers addressing the potential of immunogenetics in PCa, reporting immune-related polymorphisms associated with tumor aggressiveness, treatment toxicity and patients' prognosis. With some peculiarities, RNASEL, IL-6, IL-10, IL-1β and MMP7 have arisen as the most significant biomarkers in PCa treatment and management, having a potential clinical role. Validation prospective clinical studies are required to translate immunogenetics into precision treatment of PCa.